about
Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-beta1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis CEffect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.sPECAM-1 and sVCAM-1: Role in Pathogenesis and Diagnosis of Chronic Hepatitis C and Association with Response to Antiviral Therapy.Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.Treatment of HCV infection in Poland at the beginning of the interferon-free era - the EpiTer-2 study.Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?TGF-beta1 mRNA expression in liver biopsy specimens and TGF-beta1 serum levels in patients with chronic hepatitis C before and after antiviral therapy.The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort studyHepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clustersReal World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free TherapyEfficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer studyPrevalence of HCV genotypes in Poland - the EpiTer studyDurability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience studyReal-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1Real life results of direct acting antiviral therapy for HCV infection in HIV-HCV-coinfected patients: Epi-Ter2 study
P50
Q33788611-F19A4036-D999-44DD-B563-748F0B8C3718Q36255875-AE139AE1-02C1-4553-BF6F-49CB1BB302C3Q36391682-5B1B47D0-1012-48EB-851F-C9E35EC23748Q39006501-9C04A7A0-D723-41D6-B7A9-85AD8C3C8803Q39406860-484A24AD-F24E-4AD8-A6B4-C48F57CA0764Q41172648-0D4965CE-D9B8-4EF6-A450-B1741B2DA95BQ43623654-DC50474D-4CE9-45E1-B87C-5C223A7D502CQ47189085-8C400465-D72E-4450-82CA-E0045AAAE3B7Q50004244-7956FBF1-DAE8-41F7-B5C1-D990643BA200Q50578991-B156691A-66EF-4ECC-8ECC-4A3A80A5A864Q59330347-7CEAE266-A7F8-4AE2-A473-F025382491EFQ59357466-D958C441-A018-4871-AFD6-629AB50F9685Q64070542-1C171923-FEC4-46FA-8A3A-BE4480210573Q88881146-67FE7162-643B-4553-A86F-BEC3CC56C494Q88881150-7A2EF9C5-F49E-455F-B19C-1479961A1587Q89059935-CE9916B8-9FD7-4A2E-8A94-82CD8C364AD1Q90923842-36D11BCF-F6EE-493B-AE95-B090F55D3B4DQ91262277-3B9CA760-FDCB-4EB7-8B97-53A9E5017B0BQ92179269-2BD3565B-9E16-4179-ABBE-0B5F2ADAA1EB
P50
description
Polish researcher
@en
Pools onderzoekster
@nl
cercetătoare poloneză
@ro
chercheuse polonaise
@fr
investigadora polaca
@es
investigadora polaca
@gl
investigadora polonesa
@ca
polnische Forscherin
@de
polska naukowiec
@pl
ricercatora polacca
@it
name
Ewa Janczewska
@ast
Ewa Janczewska
@ca
Ewa Janczewska
@de
Ewa Janczewska
@en
Ewa Janczewska
@es
Ewa Janczewska
@fr
Ewa Janczewska
@ga
Ewa Janczewska
@gl
Ewa Janczewska
@it
Ewa Janczewska
@nl
type
label
Ewa Janczewska
@ast
Ewa Janczewska
@ca
Ewa Janczewska
@de
Ewa Janczewska
@en
Ewa Janczewska
@es
Ewa Janczewska
@fr
Ewa Janczewska
@ga
Ewa Janczewska
@gl
Ewa Janczewska
@it
Ewa Janczewska
@nl
prefLabel
Ewa Janczewska
@ast
Ewa Janczewska
@ca
Ewa Janczewska
@de
Ewa Janczewska
@en
Ewa Janczewska
@es
Ewa Janczewska
@fr
Ewa Janczewska
@ga
Ewa Janczewska
@gl
Ewa Janczewska
@it
Ewa Janczewska
@nl
P106
P1412
P1559
Ewa Janczewska
@pl
P21
P27
P31
P496
0000-0002-5406-4603